Clinical Trials
20 trialsNCT02000882 2022-02-07
STAR Cape+BKM120 MBC With Brain Met
US Oncology Research
Phase 2 Completed
NCT01623349 2021-02-10
Phase I Study of the Oral PI3kinase Inhibitor BKM120 or BYL719 and the Oral PARP Inhibitor Olaparib in Patients With Recurrent Triple Negative Breast Cancer or High Grade Serous Ovarian Cancer
Dana-Farber Cancer Institute
Phase 1 Completed
NCT01576666 2020-12-19
Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors
Novartis
Phase 1 Completed
NCT02154776 2020-12-19
LeeBLet
Novartis
Phase 1 Completed
NCT02088684 2020-12-17
Study of LEE011 With Fulvestrant and BYL719 or BKM120 in Advanced Breast Cancer
Novartis
Phase 1 Completed
NCT01155453 2020-12-09
A Study to Investigate Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of BKM120 Plus GSK1120212 in Selected Advanced Solid Tumor Patients
Novartis
Phase 1 Completed
NCT01626209 2020-12-09
A Phase I Study of BKM120 in Adult Chinese Patients With Advanced Solid Tumors
Novartis
Phase 1 Completed
NCT01068483 2020-12-08
Safety of BKM120 Monotherapy in Advanced Solid Tumor Patients
Novartis
Phase 1 Completed
NCT01629615 2020-10-28
A Trial of BKM120 (a PI3K Inhibitor) in Patients With Triple Negative Metastatic Breast Cancer
SOLTI Breast Cancer Research Group
Phase 2 Completed
NCT01363232 2020-10-05
Safety, Pharmacokinetics and Pharmacodynamics of BKM120 Plus MEK162 in Selected Advanced Solid Tumor Patients
Array BioPharma
Phase 1 Completed
NCT01610284 2020-08-25
BELLE-2
Novartis
Phase 3 Completed
NCT02058381 2020-03-09
B-YOND
Novartis
Phase 1 Completed
NCT01816594 2019-11-14
NeoPHOEBE
Novartis
Phase 2 Completed
NCT01790932 2019-01-23
BKM120 For Triple Negative Breast Cancer
Dana-Farber Cancer Institute
Phase 2 Completed
NCT01923168 2018-09-14
Study of Letrozole With or Without BYL719 or Buparlisib, for the Neoadjuvant Treatment of Postmenopausal Women
Novartis
Phase 2 Completed
NCT02404844 2018-04-20
PIKTAM
University Hospital, Essen
Phase 2 Completed
NCT01572727 2017-03-09
BELLE-4
Novartis
Phase 2/3 Completed
NCT01339442 2017-01-25
BKM120 and Fulvestrant for Treating Postmenopausal Patients With Estrogen Receptor-Positive Stage IV Breast Cancer
Washington University School of Medicine
Phase 1 Completed
NCT01248494 2016-07-25
PhIb BKM120 or BEZ235+Endocrine Treatment in Post-Menopausal Patients With Hormone Receptor + Metastatic Breast Cancer
Vanderbilt-Ingram Cancer Center
Phase 1 Completed
NCT01513356 2014-04-02
Pharmacodynamic Study of BKM120 in Breast Cancer
Grupo Hospital de Madrid
Phase EARLY_PHASE1 Completed